Ocugen, Inc.
OCGNNASDAQHealthcare● Active
$1.27
$-0.01(-0.68%)
Market Cap$430362836
P/E Ratio—
52W High$2.725
52W Low$0.9
Ocugen, Inc. (OCGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OCGN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.06
Est. -$0.05 · -20.0%
Revenue
$0.00B
Est. $0.00B · +266.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
OCGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.00B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.05 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.05 | -$0.06 | -20.0% | $0.00B | $0.00B | +266.9% |
| — Q1 FY2026 | Mar 4, 2026 | -$0.06 | -$0.06 | +0.0% | $-0.00B | $0.00B | -118.0% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.06 | -$0.07 | -21.7% | $0.00B | $0.00B | +298.2% |
| ▲ Q3 FY2025 | Aug 1, 2025 | -$0.06 | -$0.05 | +16.7% | $0.00B | $0.00B | +357.7% |
| ▲ Q2 FY2025 | May 9, 2025 | -$0.06 | -$0.05 | +16.7% | $0.00B | — | — |
| — Q1 FY2025 | Mar 5, 2025 | -$0.05 | -$0.05 | +0.0% | $0.00B | $0.00B | +91.0% |
| — Q4 FY2024 | Nov 8, 2024 | -$0.05 | -$0.05 | +0.0% | $0.00B | $0.00B | +184.0% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.06
EPS Est.
-$0.05
EPS Surpr.
-20.0%
Revenue
$0.00B
Q1 FY2026
Mar 4, 2026
EPS Actual
-$0.06
EPS Est.
-$0.06
EPS Surpr.
+0.0%
Revenue
$-0.00B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.07
EPS Est.
-$0.06
EPS Surpr.
-21.7%
Revenue
$0.00B
Q3 FY2025
Aug 1, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
$0.00B
Q2 FY2025
May 9, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
$0.00B
Q1 FY2025
Mar 5, 2025
EPS Actual
-$0.05
EPS Est.
-$0.05
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2024
Nov 8, 2024
EPS Actual
-$0.05
EPS Est.
-$0.05
EPS Surpr.
+0.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q4 FY2027 | $-0.06 | $-0.05 | $-0.04 | 2 |
| Q3 FY2027 | $-0.09 | $-0.07 | $-0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -20.0% | $1.85 | $1.49 | -19.46% |
| ▲ Q1 FY2026 | Mar 4, 2026 | +0.0% | $1.86 | $1.96 | +5.38% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -21.7% | $1.43 | $1.41 | -1.40% |
| ▲ Q3 FY2025 | Aug 1, 2025 | +16.7% | $1.03 | $0.99 | -3.53% |
| ▲ Q2 FY2025 | May 9, 2025 | +16.7% | $0.69 | $0.67 | -2.81% |
| ▲ Q1 FY2025 | Mar 5, 2025 | +0.0% | $0.59 | $0.57 | -2.80% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +0.0% | $1.08 | $0.99 | -8.69% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +33.3% | $1.18 | $1.28 | +8.47% |
Q2 FY2026-19.46%
Report Date
May 5, 2026
EPS Beat/Miss
-20.0%
Price Before
$1.85
Price After
$1.49
Q1 FY2026+5.38%
Report Date
Mar 4, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.86
Price After
$1.96
Q4 FY2025-1.40%
Report Date
Nov 5, 2025
EPS Beat/Miss
-21.7%
Price Before
$1.43
Price After
$1.41
Q3 FY2025-3.53%
Report Date
Aug 1, 2025
EPS Beat/Miss
+16.7%
Price Before
$1.03
Price After
$0.99
Q2 FY2025-2.81%
Report Date
May 9, 2025
EPS Beat/Miss
+16.7%
Price Before
$0.69
Price After
$0.67
Q1 FY2025-2.80%
Report Date
Mar 5, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.59
Price After
$0.57
Q4 FY2024-8.69%
Report Date
Nov 8, 2024
EPS Beat/Miss
+0.0%
Price Before
$1.08
Price After
$0.99
Q3 FY2024+8.47%
Report Date
Aug 8, 2024
EPS Beat/Miss
+33.3%
Price Before
$1.18
Price After
$1.28
Avg Beat Reaction-0.66%
Avg Miss Reaction-10.43%
Beat Rate6 / 8 quarters
Largest Move-19.46% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OCGN ends December
Ocugen, Inc. (OCGN) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.06 — missing the analyst consensus of $-0.05 by -20.0%. The next OCGN earnings date is expected around September 1, 2026.
Each quarter, investors track OCGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OCGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OCGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OCGN earnings · 5 questionsOcugen, Inc.'s next earnings report is expected around September 1, 2026. OCGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OCGN historically reports after market close (AMC).
OCGN earnings datewhen is OCGN earningsOCGN next earnings datewhen does OCGN report earningsOCGN earnings calendar
▸ Source: FMP · Ocugen, Inc. SEC filings · US GAAP · Ocugen, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026